Arbutus Biopharma Corp (ABUS) stock
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3082% below fair value
$3.88+0.06 (+1.57%)
Close on Nov 11, 2026Market cap $767.65MP/E 3.5Yield –
Arbutus Biopharma statistics
79 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Mar 22, 2027 (estimated, before the open)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 11, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 8.95
- 2.39
- P/OCF Ratio
- 3.47
- 13.10
Enterprise valuationIndustry
- EV / Sales
- 2.37
- 2.66
- EV / EBIT
- 2.92
- 19.03
Share statisticsIndustry
- Shares Change (YoY)
- 2.63%
- 10.9%
- Shares Change (QoQ)
- 0.83%
- 0.51%
- Float
- 127M
- 49M
- Shares Held by Insiders
- 35.9%
- 11.6%
- Shares Held by Institutions
- 71.1%
- 56.4%
Short sellingIndustry
- Short Interest
- 20M
- –
- Short Interest Change
- -19.0%
- -0.76%
- Short % of Float
- 15.7%
- 9.06%
- Short % of Shares Outstanding
- 10.1%
- 6.38%
- Days to Cover
- 9.14
- 5.16
Stock price statisticsIndustry
- 52-Week High
- $5.45
- –
- 52-Week Low
- $3.50
- –
- 20-Day Moving Average
- $4.08
- –
- 50-Day Moving Average
- $4.50
- –
- 200-Day Moving Average
- $4.48
- –
- Average True Range (14)
- $0.19
- –
- Price Change (1 Week)
- -4.43%
- -0.50%
- Price Change (1 Month)
- -5.60%
- -0.33%
- Price Change (3 Months)
- -15.3%
- -17.2%
- Price Change (6 Months)
- -9.98%
- -20.1%
- Price Change (YTD)
- -19.3%
- -20.1%
- Price Change (1 Year)
- -15.5%
- -19.3%
- Price Change (3 Years)
- 119.2%
- -23.4%
- Price Change (5 Years)
- 11.8%
- -76.4%
- Price Change (10 Years)
- 38.6%
- -62.4%
- Average Volume (10 Days)
- 3M
- –
- Average Volume (20 Days)
- 2M
- –
- Average Volume (90 Days)
- 4M
- –
- Relative Volume
- 0.52
- 0.73
- Relative Strength Index (14)
- 39.8
- 47.6
- Volatility (1 Year)
- 46.1%
- 80.2%
- Beta (5 Years)
- 0.55
- 1.07
MarginsIndustry
- EBITDA Margin
- 81.1%
- -25.0%
Returns on capitalIndustry
- Return on Equity (ROE)
- 269.6%
- -51.3%
- Return on Assets (ROA)
- 100.6%
- -40.3%
- Return on Capital Employed (ROCE)
- 150.5%
- -37.7%
Financial positionIndustry
- Current Ratio
- 1.40
- 3.30
- Quick Ratio
- 1.40
- 2.37
- Interest Coverage
- 2299.38
- -6.27
GrowthIndustry
- Revenue Growth (YoY)
- 1142.6%
- 6.82%
- Revenue Growth (3Y CAGR)
- -28.8%
- 2.25%
- Revenue Growth (5Y CAGR)
- 15.3%
- 6.41%
EfficiencyIndustry
- Asset Turnover
- 0.83
- 0.40
- Revenue Per Employee
- $9.55M
- $426.63K
- Profits Per Employee
- $11.57M
- -$680.86K
- Employee Count
- 19
- 75
- WACC
- 7.64%
- 10.1%
Income statement (TTM)Industry
Balance sheetIndustry
- Net Cash (Debt)
- $337.49M
- $16.31M
- Net Cash Per Share
- $1.71
- $0.70
- Equity (Book Value)
- $85.75M
- $53.12M
- Book Value Per Share
- $0.43
- $1.49
- Tangible Book Value
- $85.75M
- $26.11M
- Working Capital
- $97.63M
- $77.59M
Cash flow (TTM)Industry
Dividends and yieldsIndustry
- Earnings Yield
- 28.6%
- -19.8%
Taxes and interestIndustry
- Interest Expense
- $64.00K
- $2.98M
Scores and fair valueIndustry
- Graham Number
- $3.30
- $19.42
- Graham Upside
- -14.8%
- -45.8%
- Altman Z-Score
- -0.64
- 0.28
- Piotroski F-Score
- 4
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ABUS | S&P 500 | Difference | ABUS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -8.1% | -2.4% | −5.6 pts | ||
| 3 months | -16.9% | -1.2% | −15.8 pts | ||
| Year to date | -19.3% | +12.3% | −31.6 pts | ||
| 1 year | -17.6% | +12.4% | −30.1 pts | ||
| 3 years | +119.2% | +78.8% | +40.4 pts | +29.9% | +21.4% |
| 5 years | +11.8% | +75.2% | −63.4 pts | +2.3% | +11.9% |
| 10 years | +38.6% | +311.1% | −272.5 pts | +3.3% | +15.2% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
20M ABUS shares were sold short on Oct 30, 2026, down 19.0% from the previous report, or 15.69% of the shares available to trade. At recent volumes it would take 9.1 days to buy them back. Over the last 20 sessions, 54.3% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 19,888,395 | -19.0% | 2,176,284 | 9.1 |
| Oct 15, 2026 | 24,566,591 | -27.9% | 5,655,826 | 4.3 |
| Sep 30, 2026 | 34,053,358 | +84.2% | 9,652,199 | 3.5 |
| Sep 15, 2026 | 18,484,910 | -2.3% | 3,691,181 | 5.0 |
| Aug 31, 2026 | 18,916,119 | +2.5% | 6,139,181 | 3.1 |
| Aug 14, 2026 | 18,456,085 | -8.8% | 1,222,134 | 15.1 |
| Jul 31, 2026 | 20,236,241 | +3.0% | 1,478,060 | 13.7 |
| Jul 15, 2026 | 19,653,287 | +14.9% | 2,655,278 | 7.4 |
| Jun 30, 2026 | 17,111,453 | -2.3% | 3,499,322 | 4.9 |
| Jun 15, 2026 | 17,522,670 | +3.2% | 1,255,250 | 14.0 |
| May 29, 2026 | 16,982,764 | +3.3% | 1,849,722 | 9.2 |
| May 15, 2026 | 16,438,082 | -7.4% | 962,486 | 17.1 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?